IXICO PLC (GB:IXI)
LSE:IXI
Top Page
IXICO plc
(LSE:IXI)
Select Model
Select Model
Rating:51Neutral
Price Target:
7.50 p
▼(-36.17% Downside)
Action:ReiteratedDate:02/22/26
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and very bearish technicals (below key moving averages with negative MACD). A positive offset comes from supportive earnings-call guidance and order book growth, but valuation remains constrained by the company’s loss-making profile.
Positive Factors
Specialized neuroimaging analytics
IXICO's focused business model in neuroimaging and biomarker analytics creates a durable competitive niche. Deep technical expertise and regulatory-aligned services support repeat contract demand from pharma/biotech, making revenue streams sticky and aligned with long-term CNS drug development trends.
Negative Factors
Ongoing net losses
Persistent net losses and negative operating margins limit the company's ability to self-fund growth and increase dependency on external financing or dilution. Continued unprofitability constrains reinvestment capacity and raises execution risk before sustainable margin expansion is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized neuroimaging analytics
IXICO's focused business model in neuroimaging and biomarker analytics creates a durable competitive niche. Deep technical expertise and regulatory-aligned services support repeat contract demand from pharma/biotech, making revenue streams sticky and aligned with long-term CNS drug development trends.
Read all positive factors
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£7.18M
Dividend YieldN/A
Average Volume (3M)123.87K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth13.32%
EPS Growth55.07%
CountryUK
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,668,594
10 Day Avg. Volume82,815
30 Day Avg. Volume123,868
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£7.50M
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, a...
How the Company Makes Money
IXICO generates revenue through a business model focused on providing specialized services to pharmaceutical and biotech companies. Its key revenue streams include contracts for clinical trial services, which encompass imaging analysis and data ma...
IXICO plc Earnings Call Summary
Earnings Call Date:Dec 09, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 26, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for IXICO plc, with strong revenue growth, a significant increase in the order book, and successful execution of strategic initiatives. While the company reported an EBITDA loss, the reduction in loss and strong financial position indicate progress towards future profitability. The company's strategic focus on CNS and partnerships suggest continued growth potential.Positive Updates
Revenue Growth and Order Book Expansion
The company reported GBP 6.5 million in revenues for the year, reflecting a 13% growth. The order book increased from GBP 13.1 million to GBP 17.7 million, showing significant growth and providing strong future revenue visibility.
Negative Updates
EBITDA Loss
The company reported a GBP 1.3 million EBITDA loss for the year, although this was a 20% reduction from the previous year.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth and Order Book Expansion
The company reported GBP 6.5 million in revenues for the year, reflecting a 13% growth. The order book increased from GBP 13.1 million to GBP 17.7 million, showing significant growth and providing strong future revenue visibility.
Read all positive updates
Company Guidance
During the IXICO plc Final Results Investor Presentation for the fiscal year 2025, the company provided robust guidance, emphasizing a projected revenue growth of 15% for 2026, driven by a significant increase in their order book from GBP 13.1 million to GBP 17.7 million. The company highlighted its strategic focus on expanding in Alzheimer's and Parkinson's disease spaces, supported by their AI-driven biomarker analytics platform. IXICO has achieved a 13% revenue growth, reaching GBP 6.5 million in 2025, with a gross margin of nearly 50%. They serviced 23 clients across 37 projects, with a 1.5 book-to-bill ratio indicating healthy growth prospects. The company also highlighted its strategic goals to achieve sustainable profitability at a revenue threshold of GBP 9.5 million, while planning to innovate and build strategic partnerships, particularly in the areas of imaging biomarkers and AI technology integration.IXICO plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.02M | -1.95M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | |||||
| Total Assets | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | |||||
| Free Cash Flow | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Technical Analysis
Negative
11.75
Price Trends
8.64
Negative
10.00
Negative
10.80
Negative
Market Momentum
-0.19
Negative
30.13
Neutral
60.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Negative. The current price of 11.75 is above the 20-day moving average (MA) of 7.82, above the 50-day MA of 8.64, and above the 200-day MA of 10.80, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 30.13 is Neutral, neither overbought nor oversold. The STOCH value of 60.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IXI.
IXICO plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £47.50M | -137.50 | 11.97% | 2.94% | 11.92% | -33.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.18M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
48 Neutral | £2.06M | -0.72 | -89.43% | ― | 44.32% | 60.00% | |
42 Neutral | £289.56M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £8.37M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £17.56M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:IXI
IXICO plc
7.75
0.00
0.00%
GB:AVCT
Avacta Group plc
66.20
30.20
83.89%
GB:OBD
Oxford BioDynamics
0.20
-0.22
-53.57%
GB:PYC
Physiomics
0.46
0.07
16.67%
GB:HVO
Open Orphan Plc
6.90
-7.54
-52.20%
GB:APTA
Aptamer Group Plc
0.60
0.34
130.77%
IXICO plc Corporate Events
Business Operations and StrategyFinancial Disclosures
IXICO Wins £1.5m Contract Extension on Phase 2 Huntington’s Trial
Positive
Feb 12, 2026
IXICO plc, a London-listed neuroscience imaging and biomarker analytics company, has secured an extension to an existing contract with a leading international pharmaceutical client, tied to the continued progress of a Phase 2 Huntington’s di...
Business Operations and StrategyFinancial Disclosures
IXICO Wins £1.5m Extension on Global Huntington’s Disease Trial
Positive
Feb 12, 2026
IXICO plc, a London-headquartered imaging Contract Research Organisation focused on neuroscience, leverages its proprietary AI-driven platform to process imaging data and quantify biomarkers in neurological disorders, supporting hundreds of trials...
Business Operations and StrategyExecutive/Board Changes
IXICO hires US-based Chief Commercial Officer to drive growth and expand neuroimaging business
Positive
Feb 5, 2026
IXICO has appointed Tanya Voloshen as its new Chief Commercial Officer, a senior leadership role created to reinforce the company’s commercial capabilities and support its growth strategy, particularly in the United States, where she will be...
Business Operations and StrategyShareholder Meetings
IXICO Secures Strong Shareholder Backing as All AGM Resolutions Pass
Positive
Jan 23, 2026
IXICO plc reported that all resolutions at its Annual General Meeting were passed with overwhelming shareholder support, including the receipt of the company’s accounts, the re-election of all board directors, the reappointment of its audito...
Business Operations and StrategyExecutive/Board Changes
IXICO plc Issues Share Options to Leadership Team
Positive
Dec 9, 2025
IXICO plc has announced the issuance of 1,400,000 share options to its broader leadership team, with vesting criteria tied to retention and annual revenue growth over three years. This strategic move aims to align leadership incentives with compan...
Business Operations and StrategyFinancial Disclosures
IXICO plc Reports Strong Financial Growth and Strategic Expansion
Positive
Dec 9, 2025
IXICO plc reported a strong financial performance for the year ended 30 September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss. The company’s strategic focus on innovation, leadership, and scaling has resulted in s...
Business Operations and StrategyFinancial Disclosures
IXICO plc Reports Strong Financial Growth and Strategic Expansion
Positive
Dec 9, 2025
IXICO plc reported strong financial results for the year ending September 2025, with a 13% increase in revenue and a 21% reduction in EBITDA loss, driven by its Innovate Lead Scale strategy. The company achieved significant growth in its order boo...
Business Operations and StrategyExecutive/Board Changes
IXICO Enhances Advisory Board with Alzheimer’s and Vascular Experts
Positive
Dec 1, 2025
IXICO plc has announced the appointment of two renowned experts in Alzheimer’s Disease and cerebrovascular disease to its Scientific Advisory Board, strengthening its focus on dementia research and product innovation, particularly in vascula...
Business Operations and StrategyFinancial Disclosures
IXICO plc to Announce 2025 Full Year Results and Host Investor Presentation
Neutral
Nov 27, 2025
IXICO plc has announced it will release its Full Year Results for the year ending 30 September 2025 on 09 December 2025. The company’s CEO, Bram Goorden, and CFO, Grant Nash, will present the results and discuss the company’s progress ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.